Sichuan University
scu.edu.cnTotal trials
100
Active
51
Phase 3
4
Total enrollment
8,099
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 52 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Chemotherapy | — | — | — | — | 6 | ||
| Carboplatin | — | — | — | 7 | |||
| Etoposide | — | — | — | 6 | |||
| Sintilimab | — | — | — | — | 5 | ||
| Tislelizumab | — | — | — | — | 4 | ||
| Cisplatin | — | — | — | 5 | |||
| Immunotherapy | — | — | — | — | 2 | ||
| Ivonescimab | — | — | — | — | — | 2 | |
| blinatumomab | — | — | — | — | 3 | ||
| Chidamide | — | — | — | — | 6 | ||
| Ruxolitinib | — | — | — | — | — | 2 | |
| Low-Dose Radiation | — | — | — | — | — | 1 | |
| PD-1 Inhibitor plus Chemotherapy | — | — | — | — | — | 1 | |
| S-1, Oxaliplatin sintilimab HIPEC | — | — | — | — | — | 1 | |
| Sugemalimab | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| BL-B01D1 | — | — | — | — | — | 1 | |
| Almonertinib | — | — | — | — | — | 1 | |
| Adebrelimab | — | — | — | — | — | 1 | |
| High dose Gemcitabine, Busulfan, and Thiotepa as conditioning therapy | — | — | — | — | — | 1 | |
| AK104 | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| S-1 | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| AK112 | — | — | — | — | — | 1 | |
| serplulimab | — | — | — | — | — | 1 | |
| Oncolytic Virus: Administered via intratumoral injection (metastatic lesions in the neck or supraclavicular lymph nodes) once every 3 weeks, for a total of two to four doses. | — | — | — | — | — | 1 | |
| Oncolytic Virus: Administered via intratumoral injection (primary lesions) once every 3 weeks, for a total of two to four doses. | — | — | — | — | — | 1 | |
| Cadonilimab | — | — | — | — | — | 1 | |
| neoantigen-loaded dendritic cell vaccine | — | — | — | — | — | 1 | |
| gemcitabine ,oxaliplatin,anlotinib,Sintilimab | — | — | — | — | — | 1 | |
| Ensatinib | — | — | — | — | — | 1 | |
| Sunvozertinib | — | — | — | — | — | 1 | |
| Sacituzumab Tirumotecan and Anlotinib | — | — | — | — | — | 1 | |
| Nab-paclitaxel | — | — | — | — | — | 1 | |
| Toripalimab | — | — | — | — | 3 | ||
| Dual-targeting CLDN18.2 and PD-L1 CAR-T cells | — | — | — | — | — | 1 | |
| PD-1 Inhibitors | — | — | — | — | — | 1 | |
| KRAS-mutated mRNA vaccine | — | — | — | — | — | 1 | |
| Pemetrexed+carboplatin | — | — | — | — | — | 1 |
12 more active programs hidden
Next readouts
- 2023-12-31
- 2024-04-30
- 2024-07-31
- 2024-08-31
- 2024-09-30
- 2024-09-30
- 2025-03-28
- 2025-06-30
- 2025-07-31
- 2025-12-15
Top conditions
- Esophageal Cancer6
- Gastric Cancer5
- Leukemia, Lymphoid3
- Esophageal Squamous Cell Carcinoma3
- Extensive-stage Small-cell Lung Cancer3
- Esophageal Squamous Cell Carcinoma (ESCC)3
- Lung Cancer2
- Non-small Cell Lung Cancer2
Frequently asked questions about Sichuan University
- How many clinical trials does Sichuan University have on ClinicalTrials.gov?
- Sichuan University is listed as the lead sponsor on 100 clinical trials in ClinicalTrials.gov, 51 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sichuan University's trials are in Phase 3?
- 4 of Sichuan University's trials are in Phase 3, spread across 52 active drug programs.
- What therapeutic areas does Sichuan University focus on?
- Sichuan University's most-studied conditions on ClinicalTrials.gov are Esophageal Cancer, Gastric Cancer, Leukemia, Lymphoid, Esophageal Squamous Cell Carcinoma, Extensive-stage Small-cell Lung Cancer.
- When are Sichuan University's next clinical trial readouts?
- Sichuan University has 10 upcoming primary-completion readouts tracked here; the soonest is “Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT”, expected around 2023-12-31.